Physician profile
Sinan Alo
NPI 1689972168
$14,531.76
in general payments reported to CMS, 2019-2025
41 companies · $3,442 in 2025
The $3,442 reported for 2025 was more than what 89% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,595 · 2020: $1,191 · 2021: $1,463 · 2022: $2,061 · 2023: $1,369 · 2024: $1,411 · 2025: $3,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,203 · Travel and Lodging: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,202.62 |
| Travel and Lodging | $1,019.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,060.44 | 2019-2025 | Triclip, Mitraclip |
| Janssen Pharmaceuticals, INC | $1,031.56 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $878.09 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $869.65 | 2019-2025 | Farxiga, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $784.54 | 2019-2025 | Jardiance |
| Esperion Therapeutics, INC. | $706.57 | 2020-2025 | Nexletol |
| Amgen INC. | $678.50 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $650.17 | 2022-2025 | Watchman Flx, Watchman Access System, Farapulse |
| Edwards Lifesciences Corporation | $481.48 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Pascal |
| Atricure, INC. | $466.76 | 2019-2025 | Synergy Ablation System |
| Amarin Pharma, INC. | $464.51 | 2019-2021 | |
| Kestra Medical Technology Services, INC. | $447.28 | 2023-2024 | Assure Wcd |
| Merck Sharp & Dohme LLC | $431.83 | 2021-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $423.87 | 2019-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $394.44 | 2024-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sinan Alo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.